10x Genomics, Inc. TXG
Set alert
65.47 USD +3.84 +6.23%
As of Nov 3, 2:59 PM ET
62.51 Day range 66.19
12.80 52-week range 102.81
- YTD
- +301.41%
- 1 year
- +377.88%
- Open
- 63.21
- Prev close
- 61.63
- Mkt cap
- 8.52B
- Vol
- 1.51M
- Avg vol
- 3.43M
- EPS
- -0.59
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 62.51
- High
- 66.19
- Forward P/E
- 803.83
- Beta
- 2.03
- Short ratio
- 3.09
- Inst. own
- 117.29%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 74.17
- 200-d avg
- 40.57
- 1y target
- 77.50
6M chart
Events in this range
- May 7, 2026Earnings: -0.1; estimate -0.29; surprise 65.52%
- Aug 6, 2026Earnings: -0.14; estimate -0.24308; surprise 42.41%
- Sep 28, 2026Rating: Piper Sandler · Neutral → Neutral
- Sep 29, 2026Rating: Leerink Partners · Market Perform → Market Perform
- Oct 7, 2026Rating: Barclays · Overweight → Overweight
- Oct 12, 2026Rating: Canaccord Genuity · Buy → Buy
- Oct 13, 2026Rating: Morgan Stanley · Equal-Weight → Equal-Weight
- Oct 13, 2026Rating: TD Cowen · Hold → Hold
Signals (29)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 4 days ago |
| MACD: Sell Signal | Oct 30, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 28, 2026 | 6 days ago |
| SMA: Bullish | Oct 26, 2026 | 1 week ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 7, 2026 | 3 weeks ago |
| RSI: Overbought | Sep 24, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 14, 2026 | 1 month ago |
| RSI: Overbought | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| RSI: Overbought | Aug 10, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 27, 2026 | 3 months ago |
| RSI: Overbought | Jul 21, 2026 | 3 months ago |
| RSI: Overbought | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jul 9, 2026 | 3 months ago |
| RSI: Overbought | Jun 30, 2026 | 4 months ago |
Newest 20 of 29.
Analyst view
Consensus: buy
Buy
Price target (mean) 77.50 +18.4% upside
Now 65.47
- Target (low)
- 50.00
- Target (mean)
- 77.50
- Target (high)
- 110.00
Ratings (0m) 18 6 buy · 12 hold · 0 sell
- Strong buy1
- Buy5
- Hold12
- Sell0
- Strong sell0
Recommendation trend
- This month 18
- 1 month ago 19
- 2 months ago 16
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.02 | -0.04 – 0.00 | -0.0228 | +12.3% | 147.85M | -0.8% | 2 |
| Next quarter | -0.005 | -0.06 – 0.05 | 0.0705 | -107.1% | 171.51M | +3.3% | 2 |
| Current year | 0.03667 | -0.10 – 0.18 | 0.1231 | -70.2% | 620.58M | -3.5% | 3 |
| Next year | 0.07667 | 0.01 – 0.17 | 0.03667 | +109.1% | 683.34M | +10.1% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | TD Cowen | Maintained | Hold | Hold |
| Oct 13, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Oct 12, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Oct 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 29, 2026 | Leerink Partners | Maintained | Market Perform | Market Perform |
| Sep 28, 2026 | Piper Sandler | Maintained | Neutral | Neutral |
| Sep 28, 2026 | Argus Research | Initiated | — | Buy |
| Sep 9, 2026 | UBS | Maintained | Neutral | Neutral |
| Sep 1, 2026 | RBC Capital | Initiated | — | Sector Perform |
| Aug 12, 2026 | Stephens & Co. | Maintained | Overweight | Overweight |
| Aug 10, 2026 | Piper Sandler | Maintained | Neutral | Neutral |
| Aug 10, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 7, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Aug 7, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Jul 17, 2026 | Leerink Partners | Maintained | Market Perform | Market Perform |
| Jul 14, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jul 9, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Jul 8, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Jul 1, 2026 | Piper Sandler | Maintained | Neutral | Neutral |
| Jun 24, 2026 | Barclays | Maintained | Overweight | Overweight |
| May 12, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| May 12, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Apr 20, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Apr 20, 2026 | B of A Securities | Maintained | Neutral | Neutral |
| Apr 14, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 7, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Mar 31, 2026 | William Blair | Upgrade | Market Perform | Outperform |
| Mar 2, 2026 | Stifel | Maintained | Buy | Buy |
| Feb 20, 2026 | UBS | Maintained | Neutral | Neutral |
| Feb 13, 2026 | Stifel | Maintained | Buy | Buy |